Ibáñez Lourdes, Ong Ken, Valls Carme, Marcos Maria Victoria, Dunger David B, de Zegher Francis
Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Passeig de Sant Joan de Déu 2, 08950 Esplugues, Barcelona, Spain.
J Clin Endocrinol Metab. 2006 Aug;91(8):2888-91. doi: 10.1210/jc.2006-0336. Epub 2006 May 9.
Girls with precocious pubarche (PP, pubic hair at < 8 yr of age) are at high risk for early onset and rapid progression of puberty, in particular if their prenatal growth was restrained, i.e. low birth weight (LBW), and followed by rapid postnatal catch-up of weight gain. We postulated that insulin resistance contributes to early onset and rapid progression of puberty in LBW-PP girls and thus explored the puberty-delaying effects of insulin sensitization with metformin initiated shortly after PP diagnosis.
SETTING, DESIGN, AND PATIENTS: The study population consisted of 38 prepubertal LBW girls with PP attributed to exaggerated adrenarche [mean body weight, 2.4 kg; age, 7.9 yr; body mass index (BMI), 18.4 kg/m(2)]. These girls were randomly assigned to remain untreated (n = 19) or to receive metformin (n = 19; 425 mg/d) for 2 yr.
Pubertal staging, age at menarche, body composition by absorptiometry, fasting insulin, glucose, lipids, leptin, IGF-I, IGF-binding protein-1, testosterone, dehydroepiandrosterone sulfate, and SHBG were the main outcome measures.
Metformin treatment was associated with a less adipose body composition (and lower serum leptin levels) and with a 0.4-yr delay in the clinical onset of puberty (Tanner B2; 9.5 vs. 9.1 yr; P < 0.01). These findings were corroborated by a delay of at least 1 yr in the puberty-associated rise of circulating IGF-I (P < 0.01). Available results also point to a metformin-associated delay of menarche (P < 0.02). Gain in height and lean mass was not divergent between study subgroups.
The efficacy of early metformin treatment in PP girls is here extended to include not only a less adipose body composition after 2 yr but also a less advanced onset of puberty, whereas height gain is maintained. These findings open the perspective that, ultimately, metformin treatment may also prove to heighten the short adult stature of LBW-PP girls.
青春期阴毛早现(PP,8岁前出现阴毛)的女孩青春期早发及快速进展的风险高,尤其是若其出生前生长受限,即低出生体重(LBW),且出生后体重快速追赶生长。我们推测胰岛素抵抗导致低出生体重-青春期阴毛早现(LBW-PP)女孩青春期早发及快速进展,因此探讨了在PP诊断后不久开始使用二甲双胍进行胰岛素增敏对青春期延迟的影响。
设置、设计与患者:研究人群包括38例青春期前LBW女孩,其PP归因于肾上腺初现亢进[平均体重2.4kg;年龄7.9岁;体重指数(BMI)18.4kg/m²]。这些女孩被随机分为不治疗组(n = 19)或接受二甲双胍治疗组(n = 19;425mg/d),为期2年。
青春期分期、初潮年龄、通过吸收法测定的身体成分、空腹胰岛素、血糖、血脂、瘦素、胰岛素样生长因子-I(IGF-I)、IGF结合蛋白-1、睾酮、硫酸脱氢表雄酮和性激素结合球蛋白是主要观察指标。
二甲双胍治疗与较少的脂肪性身体成分(及较低的血清瘦素水平)相关,且青春期临床起始延迟0.4年(坦纳B2期;9.5岁对9.1岁;P < 0.01)。循环IGF-I与青春期相关的升高延迟至少1年(P < 0.01)证实了这些发现。现有结果还表明二甲双胍使初潮延迟(P < 0.02)。研究亚组间身高和去脂体重的增加无差异。
早期二甲双胍治疗对PP女孩的疗效在此扩展至不仅2年后脂肪性身体成分减少,而且青春期起始也较晚,同时身高增长得以维持。这些发现开启了一种前景,即最终二甲双胍治疗可能还被证明可改善LBW-PP女孩成年后的矮小身材。